Internal quality assurance program for ERBB2 (HER2) testing improves the selection of breast cancer patients for treatment with trastuzumab

Pathology Research International

Volumn 2012, Issue , 2012, Pages

  Martin, Vittoria ^a   Camponovo, Antonella ^a   Ghisletta, Morena ^a   Bongiovanni, Massimo ^a   Mazzucchelli, Luca ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866239756     PISSN: None     EISSN: 2042003X     Source Type: Journal    
DOI: 10.1155/2012/261857     Document Type: Article

References (10)

1. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001 344 11 783 792 2-s2.0-0035869407 10.1056/NEJM200103153441101
2. Dinh P., de Azambuja E., Piccart-Gebhart M. J., Trastuzumab for early breast cancer: current status and future directions. Clinical Advances in Hematology and Oncology 2007 5 9 707 717 2-s2.0-38449123351
3. Wolff A. C., Hammond M. E. H., Schwartz J. N., Hagerty K. L., Allred D. C., Cote R. J., Dowsett M., Fitzgibbons P. L., Hanna W. M., Langer A., McShane L. M., Paik S., Pegram M. D., Perez E. A., Press M. F., Rhodes A., Sturgeon C., Taube S. E., Tubbs R., Vance G. H., Van De Vijver M., Wheeler T. M., Hayes D. F., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 2007 25 1 118 145 2-s2.0-33847147313 10.1200/JCO.2006.09.2775
4. Sauter G., Lee J., Bartlett J. M. S., Slamon D. J., Press M. F., Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. Journal of Clinical Oncology 2009 27 8 1323 1333 2-s2.0-62449090881 10.1200/JCO.2007.14.8197
5. Bartlett J. M. S., Ibrahim M., Jasani B., Morgan J. M., Ellis I., Kay E., Connolly Y., Campbell F., O'Grady A., Barnett S., Miller K., External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme. American Journal of Clinical Pathology 2009 131 1 106 111 2-s2.0-58549119992 10.1309/AJCPLN78ZQXEMNMA
6. Dowsett M., Hanna W. M., Kockx M., Penault-Llorca F., Rüschoff J., Gutjahr T., Habben K., Van De Vijver M. J., Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathology 2007 20 5 584 591 2-s2.0-34247363714 10.1038/modpathol.3800774
7. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A., Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology 2009 20 4 628 635 2-s2.0-63549108121 10.1093/annonc/mdn675
8. Brunelli M., Manfrin E., Martignoni G., Miller K., Remo A., Reghellin D., Bersani S., Gobbo S., Eccher A., Chilosi M., Bonetti F., Genotypic intratumoral heterogeneity in breast carcinoma with HER2/fieif emplification wvaluation according to ASCO/CAP criteria. American Journal of Clinical Pathology 2009 131 5 678 682 10.1309/AJCP09VUTZWZXBMJ
9. Fleiss J. L., Statistical Methods for Rates and Proportions 1981 New York, NY, USA John Wiley & Sons
10. Blank P. R., patricia.blank@ifspm.uzh.ch Schwenkglenks M., Moch H., Szucs T. D., Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment 2010 124 2 497 507 10.1007/s10549-010-0862-7